KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line TherapyFrank Kullmann, Esther Endlicher, Arndt Hartmann et al.|Oncology|2011Cited by 46
PharmaForumDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Miaojun Wang et al.|Oncology Research and Treatment|2017Cited by 1
PharmaForumDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0
PharmaNewsDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0
Editorial Board / Contents / ImprintDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0